Home > Focus Areas > Migraine Connect > Post
3yr
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01511-y
Objective HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy of erenumab with topiramate in patients who completed the trial on study medication. Methods Post hoc sensitivity analysis was performed using the full analysis set.
Conclusions: This post hoc analysis demonstrated significantly superior efficacy of erenumab versus topiramate in achieving a ≥50% reduction in MMD with an early onset of efficacy."
• Source: The Journal of Headache and Pain
• Conclusion: “This post hoc analysis demonstrated significantly superior efficacy of erenumab versus topiramate in achieving a ≥50% reduction in MMD [monthly migraine days] with an early onset of efficacy.”
• HER-MES was the first phase 4 trial that assessed the tolerability and effectiveness of erenumab vs. standard of care (i.e., topiramate). The post hoc analysis shed light on the 50% responder rate and the decrease in MMD.
• The authors wrote, “Presented data comprised patients who showed efficacy in a dose of 92 mg of topiramate, which is within the recommended range of topiramate for migraine prevention. In addition, the results demonstrated that topiramate was an effective therapy for migraine patients tolerating the drug despite not as efficacious as erenumab.”